Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01661231
Other study ID # C1106
Secondary ID
Status Active, not recruiting
Phase N/A
First received August 2, 2012
Last updated February 2, 2017
Start date October 2012
Est. completion date October 2018

Study information

Verified date February 2017
Source Biotronik AG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

BIOFLEX-I EU is the European arm of the BIOFLEX-I IDE study (NCT01319812). Data from BIOFLEX-I EU will be pooled with data in the IDE. The objective of this study is to separately demonstrate the clinical performance of BIOTRONIK's Astron and Pulsar-18 stents in the European arm of the BIOFLEX-I IDE (NCT01319812). The Pulsar-18 stent will be used for the treatment of femoro-popliteal lesions, located in the native superficial femoral artery (SFA) or proximal popliteal artery (PPA), while the Astron stent will be used for the treatment of the common or external iliac artery lesions.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 456
Est. completion date October 2018
Est. primary completion date September 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age = 18 years

- Willingness to comply with study follow-up requirements.

- Candidate for percutaneous transluminal angioplasty (PTA).

- Life-style limiting claudication or rest pain with an ABI = 0.9 (resting or exercise). Thigh or toe brachial index (TBI) may be used / performed if ABI is inadequate.

- Written informed consent.

- One de novo, restenotic or occluded lesion representing a femoro-popliteal or iliac indication OR Two de novo, restenotic or occluded lesions representing one femoro-popliteal indication and one iliac indication on contralateral limbs - (i.e. one target lesion per limb).

- Lesions may be one solid lesion or a series of multiple, smaller lesions to be treated as one lesion.

- Subjects with bilateral, SFA/PPA disease (i.e. one SFA/PPA lesion per limb) are eligible for enrolment into the study. The target lesion will be selected at the investigator's discretion based on study eligibility criteria. The contralateral SFA/PPA intervention may be performed at the time of the index procedure (prior to treatment of study lesion); however, the use of an investigational treatment is prohibited. If the contralateral SFA/PPA intervention is not performed at the time of the index procedure, the intervention must be performed at least 30 days after the index procedure. The use of an investigational treatment for the contralateral intervention is prohibited.

- Subjects with bilateral, iliac disease (i.e. one iliac lesion per limb) are eligible for enrollment into the study. The target lesion will be selected at the investigator's discretion based on study eligibility criteria. The contralateral iliac intervention may be performed at the time of the index procedure; however, the use of an investigational treatment is prohibited. If the contralateral iliac intervention is not performed at the time of the index procedure, the intervention must be performed at least 30 days after the index procedure. The use of an investigational treatment for the subsequent contralateral intervention is also prohibited.

- Femoro-popliteal lesions must be located at least 1 cm distal to the profunda femoris artery and at least 3 cm above the knee joint (radiographic joint space).

- Iliac lesions must be located only in either the common or external iliac artery.

- Lesions must be treatable with a maximum of two stents.

- Angiographic evidence of = 70% stenosis or occlusion (operator visual assessment).

- Lesion length = 190 mm (if de novo or restenotic) or = 100 mm (if occluded).

- Target vessel reference diameter: 2.5 to 6 mm (SFA/PPA) or 6 to 9 mm (iliac arteries) by visual estimate.

- Angiographic evidence of patent SFA and PPA (iliac indication) and angiographic evidence of at least one distal vessel runoff to the foot (both femoro-popliteal and iliac indications). Patent is defined as < 50% stenosis.

- For SFA/PPA intervention, a significant stenosis (> 70%) or occlusion of an ipsilateral, inflow artery (e.g. aortoiliac, common femoral) must be successfully treated with PTA and/or commercially-available stent just prior to treatment of the target lesion. Successful treatment is defined as no complications and less than 30% residual stenosis following intervention.

Exclusion Criteria:

- Subjects pregnant or planning to become pregnant during the course of the study.

- Life expectancy of less than one year.

- Rutherford-Becker category 5 or 6. Subjects with ulcers caused by venous disease may be enrolled in the study.

- Previously stented lesion(s) in the target vessel.

- Target lesion(s) received previous treatment within 30 days prior to enrollment.

- Prior peripheral vascular bypass surgery involving the target limb(s).

- Thrombophlebitis or deep vein thrombosis within the past 30 days.

- Known allergy to nitinol (nickel and/or titanium).

- Participation in any other clinical investigational device or drug study. Subjects may be concurrently enrolled in a post-market study, as long as the post-market study device, drug or protocol does not interfere with the investigational treatment or protocol of this study.

- Previous stroke or transient ischemic attack within the last three months prior to enrollment.

- Previous coronary or peripheral bypass surgery (non-target limb) within 30 days prior to enrollment.

- Intolerance to contrast agents that cannot be medically managed and/or intolerance to anti-platelet, anti-coagulant or thrombolytic medications.

- Refuses blood transfusions.

- Any medical condition, that in the opinion of the investigator, poses an unacceptable risk for implant of a stent according to the study indications.

- International Normalized Ratio (INR) = 1.6

- Concomitant renal failure with serum creatinine level > 2.5 mg/dL

- Unresolved neutropenia (white blood cell count < 3,000 / µL) or thrombocytopenia (platelet count < 80,000 / µL) at the time of the index procedure.

- Unresolved bleeding disorder (INR = 1.6) at the time of the index procedure.

- Presence of other ipsilateral, arterial lesions distal to the target lesion requiring treatment within 30 days of the index procedure (either before or after) or at the time of index procedure.

- Additional percutaneous interventional procedures (cardiac and/or peripheral) planned within 30 days after the index procedure.

- Presence of a complication following pre-dilation of target lesion.

- Presence of a target vessel/lesion that is excessively tortuous or calcified or is adjacent to an acute thrombus that is unresponsive to anti-thrombotic therapies.

- Target lesion is located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion.

- Target lesion requires the use of cutting balloons, atherectomy or ablative devices.

- Subjects with less than single vessel runoff to the foot.

Study Design


Intervention

Device:
Astron/Pulsar-18 stent
Peripheral Vascular Intervention

Locations

Country Name City State
Austria Medical University of Graz Graz
Belgium Imelda Ziekenhuis Bonheiden
Belgium AZ St.-Blasius Hospital Dendermonde
Belgium Regionaal Ziekenhuis Heilig Hart Tienen Tienen
Germany Klinikum Arnsberg, Karolinen Hospital Huesten Arnsberg
Germany Universitätsklinikum Münster Münster
Switzerland University Hospital of Bern Bern

Sponsors (2)

Lead Sponsor Collaborator
Biotronik AG Biotronik, Inc.

Countries where clinical trial is conducted

Austria,  Belgium,  Germany,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Endpoint for the Astron Stent A composite of the rate of procedure- or stent-related major adverse events (MAEs) at 12 months post-index procedure. The MAE rate includes 30-day mortality, along with 12-month rates of target lesion revascularization (TLR) and index limb amputation. 12 months
Primary Clinical Primary Endpoint for the Pulsar-18 Stent Freedom from procedure- or stent-related MAEs at 30 days post-index procedure. The MAE rate includes mortality, TLR and index limb amputation. 30 days
Primary Performance Primary Endpoint for the Pulsar-18 Stent Primary patency rate (defined as freedom from more than 50% restenosis) at 12 months post-index procedure, as measured by duplex ultrasound. 12 months
Secondary Secondary Endpoint for the Pulsar-18 Stent Contribution of the individual rates of mortality, TLR and index limb amputation at 30 days post-index procedure to the primary clinical endpoint for the Pulsar-18 stent group 30 days
Secondary Secondary Endpoint for the Astron Stent Contribution of the individual rates of 30-day mortality and 12-month TLR and index limb amputation rates to the primary endpoint for the Astron stent. 12 months
Secondary Secondary Endpoint for the Pulsar-18 Stent Evaluate the MAE rate of the Pulsar-18 stent group at 12 months post-index procedure, along with the contribution the individual rates of 30-day mortality and 12-month TLR and index limb amputation rates to the overall MAE rate 12 months
Secondary Secondary Endpoint for the Pulsar-18 Stent Evaluate the stent fracture rate for the Pulsar-18 stent group at 12 months post-index procedure. 12 months
Secondary Secondary Endpoint for the Astron Stent Evaluate the primary patency rate for the Astron stent at 12 months post-index procedure. 12 months
Secondary Secondary Endpoint for Both the Astron and Pulsar-18 Stents Evaluate the primary assisted patency rate for the Astron stent and the Pulsar-18 stent group at 12 months post-index procedure. 12 months
Secondary Secondary Endpoint for Both the Astron and Pulsar-18 Stents Evaluate the secondary patency rate for the Astron stent and the Pulsar-18 stent group at 12 months post-index procedure. 12 months
Secondary Secondary Endpoint for Both the Astron and Pulsar-18 Stents Evaluate the 30-day clinical success of the procedure. 30 days
Secondary Secondary Endpoint for Both the Astron and Pulsar-18 Stents Compare the ABI measurement(s) of the treated limb(s) between baseline and 12 months post-index procedure. 12 months
Secondary Secondary Endpoint for Both the Astron and Pulsar-18 Stents Compare the scores on the Walking Impairment Questionnaire between baseline and 12 months post-index procedure. 12 months
Secondary Secondary Endpoint for Both the Astron and Pulsar-18 Stents Evaluate the acute procedural success of the Astron stent and the Pulsar-18 stent group 30 days
Secondary Secondary Endpoint for Both the Astron and Pulsar-18 stents Evaluate the rates of all individual adverse event types that are not included in the primary endpoint analyses for the Astron and Pulsar-18 stents 12 months
Secondary Comparison of Endpoints Results Between Short and Long Lesions for Pulsar-18 Stent Compare the primary and secondary endpoint results between evaluable subjects in the Pulsar-18 stents with lesions from 20 mm to 140 mm in length and evaluable subjects with lesions from 141 mm to 190 mm in length. 12 months
Secondary Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar-18 Stents Compare the primary and secondary endpoint results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar-18 stent group. 12 months
Secondary Secondary Endpoint for Both the Astron and Pulsar-18 Stents Compare the distance walked during the six-minute walk test between baseline and 12 months post-index procedure 12 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05712395 - The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease N/A
Active, not recruiting NCT04534257 - Prospective Registry to Investigate the Safety and Efficacy of the Treatment With the Selution Sirolimus Drug Coated Balloon in TASC C and D Atheroma-occlusive Infra-Inguinal Disease in Patients With Chronic Limb Threatening Ischemia From Singapore N/A
Recruiting NCT04511234 - Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Completed NCT02554266 - Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries
Completed NCT03921905 - Peripheral Artery Disease in Patients With Stable Coronary Artery Disease in General Practice: Prevalence, Management and Clinical Outcomes.
Not yet recruiting NCT06369350 - Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion Early Phase 1
Recruiting NCT04545268 - Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance N/A
Recruiting NCT02389023 - Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery N/A
Completed NCT02539940 - Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
Completed NCT02563535 - Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Phase 4
Completed NCT02522884 - Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries N/A
Completed NCT02542267 - In-Stent Restenosis Post-Approval Study N/A
Completed NCT02228564 - BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease N/A
Completed NCT02145065 - First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r) N/A
Completed NCT02262949 - A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System N/A
Completed NCT01743872 - Optical Imaging Measurement of Intravascular Solution Efficacy Trial N/A
Recruiting NCT01424020 - Walking Estimated Limitation Calculated by History - Study 2 Phase 4
Active, not recruiting NCT01597453 - NOR-SYS: The Norwegian Stroke in the Young Study N/A